The
biological role of monocytes and macrophages in B-cell
non-Hodgkin lymphoma (NHL) is not fully understood. We have previously reported that monocytes from patients with B-cell NHL have an immunosuppressive CD14(+)
HLA-DR(low/-) phenotype that correlates with a poor prognosis. However, the underlying mechanism by which CD14(+)
HLA-DR(low/-) monocytes develop in
lymphoma is unknown. In the present study, we found that
interleukin (IL)-10, which is increased in the serum of patients with B-cell NHL, induced the development of the CD4(+)
HLA-DR(low/-) population. Using peripheral blood samples from patients with B-cell NHL, we found that absolute numbers of CD14(+) monocytic cells with an
HLA-DR(low/-) phenotype were higher than healthy controls and correlated with a higher International Prognostic Index score.
IL-10 serum levels were elevated in
lymphoma patients compared with controls and were associated with increased peripheral monocyte counts. Treatment of monocytes with
IL-10 in vitro significantly decreased
HLA-DR expression and resulted in the expansion of CD14(+)
HLA-DR(low/-) population. We found that
lymphoma B cells produce
IL-10 and supernatants from cultured
lymphoma cells increased the CD14(+)
HLA-DR(low/-) population. Furthermore, we found that IL-10-induced CD14(+)
HLA-DR(low/-) monocytes inhibited the activation and proliferation of T cells. Taken together, these results suggest that elevated
IL-10 serum levels contribute to increased numbers of immunosuppressive CD14(+)
HLA-DR(low/-) monocytes in B-cell NHL.